Eflapegrastim

DRUG3 trials

Sponsors

Spectrum Pharmaceuticals, Inc, Eunseong Medical Foundation Good GANG-AN HOSPITAL

Conditions

Breast CancerBreast NeoplasmsLymphomaNeutropeniaSolid Tumors

Phase 1

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

CompletedNCT04187898

Spectrum Pharmaceuticals, IncBreast Cancer, Neutropenia

Start: 2020-03-11End: 2024-08-16Updated: 2024-09-19

Phase 2

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

RecruitingNCT04570423

Spectrum Pharmaceuticals, IncLymphoma, Solid Tumors

Start: 2021-05-20End: 2027-10-01Target: 40Updated: 2026-09-01

Phase 4

Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

RecruitingNCT05949333

Eunseong Medical Foundation Good GANG-AN HOSPITALBreast Neoplasms

Start: 2023-11-07End: 2025-07-31Target: 100Updated: 2024-02-23

Related Papers

Abstract P4-10-22: Eflapegrastim, a long-acting GCSF, administered the same day as chemotherapy in patients with early-stage breast cancer: Results from a multicenter, open-label, study

Clinical Cancer Research2025-06-13

Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.

2024-01-094 citations

Abstract OT-06-01: Open-label, phase 1 study to evaluate duration of severe neutropenia after same-day dosing of eflapegrastim in patients with breast cancer receiving docetaxel and cyclophosphamide (NCT04187898)

Cancer Research2021-02-15